Aims Impaired lung function associates with deterioration of glycemic control and diabetes-related oxidative stress in longstanding type 2 diabetes. We hypothesized that recent-onset type 2 diabetes patients exhibit abnormal pulmonary function when compared to glucose-tolerant controls and that the frequencies of single-nucleotide polymorphisms (SNPs), known to associate with lung dysfunction, are different between both groups.
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ABStR Ac t
Aims Impaired lung function associates with deterioration of glycemic control and diabetes-related oxidative stress in longstanding type 2 diabetes. We hypothesized that recent-onset type 2 diabetes patients exhibit abnormal pulmonary function when compared to glucose-tolerant controls and that the frequencies of single-nucleotide polymorphisms (SNPs), known to associate with lung dysfunction, are different between both groups.
Methods Type 2 diabetes patients with a known disease duration < 1 year (n = 34) had similar age, sex distribution and BMI as overweight controls (n = 26). Lung function was assessed by spirometry comprising predicted forced vital capacity (FVC %), predicted forced expiratory volume in one second (FEV1 %) and the FEV1/FVC ratio. Multivariable linear regressions were performed to investigate group differences, which were adjusted for potential confounders such as age, sex, BMI, height and smoking status. SNP genotyping was conducted using realtime polymerase chain reaction-based allelic discrimination.
Results Patients with type 2 diabetes had lower FEV1 %, FEV1/ FVC and VO 2max (all p < 0.05). Among patients with type 2 diabetes, FEV1 % correlated positively with VO 2max (r = 0.40, p < 0.05) and FEV1/FVC correlated negatively with HbA 1c (r = − 0.49, p < 0.01). Regression analyses across the whole cohort indicated that the group differences in FEV1/FVC can be explained by the confounding effect of HbA 1c . The frequencies of the SNPs rs1042713, rs1079572, rs11172113, rs12504628, rs1422795, rs1481345, rs2235910, rs2277027, rs2284746, rs4341, rs7068966, rs925284, rs993925 and rs3824658 did not differ between both groups.
Conclusions Recent-onset type 2 diabetes patients exhibit reductions in features of pulmonary function, which might be at least in part resulting from glucotoxicity.
Introduction
Impaired pulmonary function predicts morbidity and mortality [1] . Lung function deteriorates with longer diabetes duration [2] . Thus, impaired pulmonary function may be a potential complication of long-standing type 2 diabetes mellitus [3] . Indeed, cohorts of patients with long-term type 2 diabetes mellitus show pathological breathing patterns [2] and an increased prevalence for pulmonary disorders such as chronic obstructive pulmonary disease (COPD), asthma or fibrosis [4] .
Hyperglycemia and diabetes-related oxidative stress have been linked to respiratory muscle dysfunction and pulmonary impairment in patients with long-term type 2 diabetes mellitus [5, 6] . Moreover, impaired lung function has been associated with worsening of glycemic control in patients with long-term type 2 diabetes mellitus, with negative associations of fasting plasma glucose or hemoglobin A1c (HbA 1c ) with pulmonary function [7] .
The ratio of forced expiratory volume in one second (FEV1) over forced vital capacity (FVC) reflects airflow obstructions (FEV1/FVC). Particularly, predicted FEV1 (FEV1 %) quantifies the severity of obstruction, whereas predicted FVC (FVC %) defines restrictive lung diseases [3] . Of note, not only environmental risk factors, including smoking [8] , but also single nucleotide polymorphisms (SNP) within certain genes may contribute to the prediction of pulmonary dysfunction [9] . Recently, genome-wide association studies (GWAS) identified specific SNPs to be associated with impaired pulmonary function [10] . Some of these SNPs have been described previously in the context of diabetes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , such as abnormal pancreatic beta cell function, e. g. CDC123 [19] , impaired thermogenesis, e. g. MFAP2 [14] , or diabetes-related comorbidities, e. g. TGFB2 [22] .
However, the relationships between lung function and maximal oxygen consumption, genetic variation and glycemic control have not been investigated in the early course of type 2 diabetes mellitus. Here, we hypothesized that (i) patients with newly diagnosed type 2 diabetes mellitus have reduced lung function compared to glucose-tolerant humans, (ii) lung function (FEV1 %, FVC % and FEV1/FVC) associates positively with maximal oxygen consumption and negatively with glycemic control and that (iii) the frequency of SNPs known to associate with various lung dysfunction traits differ in both groups.
Materials and Methods

Study design
Participants aged 18-69 years were recruited consecutively from the baseline cohort of the ongoing German Diabetes Study (GDS), a prospective observational study investigating the natural course of metabolic abnormalities as well as the development of diabetesassociated chronic complications in individuals with newly diagnosed type 1 or type 2 diabetes mellitus (known diabetes duration < 1 year) compared to glucose-tolerant humans serving as control group [23] . All included controls had no first-degree relatives with diabetes and were glucose tolerant based on an oral glucose tolerance test. The study design and cohort profile has been described in detail before [23] and pulmonary function testing was introduced into the GDS study protocol in 2014. Informed consent was obtained from all volunteers prior to inclusion into the trial (ClinicalTrial.gov registration no: NCT01055093), which was approved by the ethics board of Heinrich Heine University Düsseldorf. All patients with recent diagnosis of type 2 diabetes mellitus and metabolically healthy controls enrolled into GDS between August 2014 and December 2016 with complete data sets for parameters of lung function were included in this analysis.
Spiroergometry
Each participant underwent a pulmonary function test as part of the GDS study protocol. FEV1 %, FVC %, and FEV1/FVC were evaluated in accordance with the Task Force of the Global Lung Function Initiative (GLI) and European Respiratory Society (ERS) from 2012. This examination was followed by an incremental exhaustive exercise test described in detail elsewhere [23] . At the end of the test, maximal oxygen consumption (VO 2 max), maximum heart rate (HR max ) and oxygen pulse (O 2 -pulse), which was calculated as the ratio of VO 2 max and HR max [24] , were recorded. Exhaustion was defined in accordance with the statement of the American Thoracic Society/American College of Chest Physicians (ATS/ACCP) on cardiopulmonary exercise testing from 2003 by the presence of one or more of the following criteria: (i) respiratory exchange ratio (RER) > 1.15 or if (ii) predicted HR max , (iii) predicted VO 2 max and/ or a plateau, or (iv) predicted maximal work rate were achieved [25] . Participants not matching the exhaustion criteria during spiroergometry as defined by ATS/ACCP or suffering from known pulmonary diseases, such as chronic obstructive pulmonary disease or cystic fibrosis, were excluded from the final analysis.
Laboratory analyses
HbA 1c as a parameter of glycemic control and high-sensitive C-reactive protein (hs-CRP) were measured under fasting conditions as previously described [23] .
Genotyping
Genomic DNA was extracted from whole blood using a blood extraction kit (Qiagen, Hilden, Germany). SNP genotyping was conducted using real-time polymerase chain reaction-based allelic discrimination according to manufacturers' recommendations with probe-based genotyping assays for the SNPs rs4341 (ACE; C_29403047_10), rs1422795 (ADAM19; C_7537507_20), rs2277027 (ADAM19; C_15883185_10), rs1042713 (ADRB2; C_2084764_20), rs7068966 (CDC123; C_29081582_20), rs12504628 (HHIP; C_1172355_10), rs925284 (HOXB7; C_1570182_10), rs3824658 (ITIH5; C_970260_10), rs11172113 (LRP1; C_1955075_10), rs2284746 (MFAP29; C_15961773_20), rs2235910 (PADI2; C_15953294_10), rs1481345 (TGFB2; C_9618884_10), rs993925 (TGFB2; C_8852342_10), and rs1079572 (WWOX; C_2373105_20) (Assay ID; Life Technologies, Darmstadt, Germany). The genotype concordance of > 99.9 % was determined using TaqMan Genotyper software v.1.3 (Life Technologies) [23] .
Statistical analyses
Data are presented as means and standard deviations (mean ± SD) or when appropriate, as median and 1 st and 3 rd quartiles (median (1 st ; 3 rd quartiles)). Multivariable least-squares regression analyses
Article Thieme adjusted for age, sex, body mass index (BMI), height, and smoking status were used to study the association between parameters of lung function with HbA 1c and VO 2 max. Multivariable linear leastsquares regression was carried out to investigate group differences between patients with type 2 diabetes mellitus and glucose-tolerant controls while adjusting for potential confounders such as age, sex, BMI, height, and smoking status. Power calculation revealed that with the sample size of this study only differences in lung function larger than 0.85 SD between both groups can be detected with a power of at least 80 %. The association between the specific SNPs and pulmonary function was tested using multivariable leastsquares regression analyses adjusting for the above-mentioned confounders and diabetes status. P-values from two-sided tests less than 5 % were considered to indicate significant differences. For the analysis of SNPs, the Bonferroni correction was applied to correct for multiple testing by dividing the significance level by the number of tests. Fishers exact test was used to compare frequencies of SNPs between patient groups. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Patients with type 2 diabetes mellitus did not differ in age, sex distribution, BMI, height, O 2 -pulse and smoking status from glucosetolerant persons (▶ table 1). After adjusting for age, sex, BMI, height, and smoking status, the patients had higher HbA 1c and hs-CRP (both p < 0.05) and lower values of VO 2 max than the controls (p < 0.05). Patients with recently diagnosed type 2 diabetes mellitus also had reduced lung function as assessed by FEV1 % (▶ table 1) and FEV1/FVC (-9 %) (▶Fig. 1) (both p < 0.01).
Correlation analyses of data from patients with type 2 diabetes mellitus revealed that FEV1/FVC negatively associated with HbA 1c (r = − 0.49; p = 0.008) and FEV1 % positively associated with VO 2 max (r = 0.39; p = 0.039). No associations were found among glucosetolerant controls (data not shown). To investigate whether the group differences in HbA 1c and VO 2 max explain group differences in FEV1/FVC and FEV1, we combined the groups and first fitted a ▶table 1 Demographic and clinical characteristics of the study participants. (current smoker/former smoker/non-smoker). * * Glucose-lowering treatment: (metformin monotherapy/diet/other glucose-lowering medication (no insulin)/metformin + other glucose-lowering medications (no insulin)). BMI, body mass index; FEV1 %, predicted forced expiratory volume in one second; FVC %, predicted forced ventilation capacity; HbA 1c , hemoglobin A1c; HR max , maximum heart rate; hs-CRP, high sensitive C-reactive protein; VO 2 max, maximal oxygen consumption regression model allowing for different intercepts and slopes for controls and patients with type 2 diabetes mellitus. The test for interaction (different slopes) was not significant in both regression models (FEV1/FVC model: p = 0.618; FEV1 model: p = 0.742). Assuming equal slopes for both groups, a simplified FEV1 model yielded a common slope of 0.07 per unit increase of VO 2 max (p < 0.0001), but different intercepts (1.16 for type 2 diabetes mellitus vs. 1.61 for controls, p = 0.014). Thus, the confounding effect of VO 2 max on FEV1 cannot fully explain the group differences in FEV1 (▶ Fig. 2a) . The simplified FEV1/FVC model also yielded no difference in the intercepts (1.11 for type 2 diabetes mellitus vs. 1.12 for controls, p = 0.782). For this reason, the model was further simplified by assuming common intercepts, which lead to the final model (common intercept: 1.14, common slope: -0.07 per unit increase of HbA 1c p = 0.001) (▶Fig. 2b). This indicates that the group differences in FEV1/FVC can be explained by the confounding effect of HbA 1c .
Allelic and genotypic frequencies of the selected genes are summarized in Supplementary table 1S. Analysis of genotypic frequencies between both groups did not reveal any differences (table 2S) . Furthermore, the selected SNPs did not associate with pulmonary function within the whole group (table 3S).
Discussion and Conclusions
This study shows that patients with newly diagnosed type 2 diabetes mellitus already exhibit evidence for reduced lung function when compared to a control group of glucose-tolerant humans matched for age, sex, BMI and smoking status. This reduction elucidates a typical obstructive breathing pattern with reduced values of FEV1 % and FEV1/FVC in patients with recent-onset type 2 diabetes mellitus. In contrast, patients with long-standing and severe type 2 diabetes mellitus showed in prospective analyses a primary restrictive breathing pattern with a fast decline of FVC, indicating possible diabetes-related changes of the lung [2] .
Furthermore, glycemic control correlated negatively with lung function even after adjustment for age, sex, BMI, height, and smoking status. These results extend previous studies showing that reduced pulmonary function correlates negatively with increased HbA 1c in patients with inadequate glycemic control and long-term type 2 diabetes mellitus [3] . Our findings indicate that even subtle changes in glycemia can affect lung function in patients with very good glycemic control in the early course of diabetes. In line with this finding, previous studies showed an association between prediabetes and lung function [26, 27] . However, progression of lung diseases, such as COPD, may predispose to impairment of glycemic control, though not reported by all studies [28] . Likewise, in a metabolically healthy population, an increase in HbA 1c within the normal range was associated with a decline in pulmonary function [29] . Although the underlying mechanisms are currently unknown, advanced glycation end-products (AGEs) may play a role in this context. AGEs may initiate adaptive immune reactions and reactive oxygen species (ROS) production, leading to microvascular damages and structural changes (e. g. thickening of alveolar epithelial basal laminae) and, consequently, to impaired lung function [29] . Indeed, some experimental human data support the concept of an association between AGEs and lung function or increased severity of lung pathologies [29] .
Inflammation could be another mechanism contributing to reduced pulmonary capacity [7] . In the present study, hs-CRP did not correlate with lung function (FEV1 %: r = − 0.16, p = 0.408; FEV1/ FVC: r = 0.11, p = 0.563). Other studies on patients with long-term type 2 diabetes mellitus demonstrated that hs-CRP associates negatively with lung function. This may result from differences in disease duration compared to our study including only patients with short known disease duration [7] .
The present study also revealed that VO 2 max correlated positively with FEV1 % in patients with newly diagnosed type 2 diabetes mellitus, even after multiple adjustments. VO 2 max represents the maximal physical capacity and epidemiological studies have shown that physical inactivity is associated with reduced lung function [30] indicating that physical activity can be a preventive or therapeutic approach to counteract reduced pulmonary capacity or that maybe a reduced lung function could lead to lower physical activity levels. Besides physical capacity, VO 2 max also reflects whole-body mitochondrial function [31] . Recent studies demonstrated that type 2 diabetes mellitus is characterized by impaired mitochondrial function and increased ROS production [32], altered The strengths of this study comprise detailed phenotyping of the participants with state-of-the-art measurements of key parameters in patients with newly diagnosed type 2 diabetes mellitus. Limitations comprise a lack of generalizability because of the wellcontrolled patients with type 2 diabetes mellitus with a mean HbA 1c of 6.4 % (46 mmol/mol), the cross-sectional approach and the low number of participants. However, our power calculation revealed that we were able to detect, with a power of at least 80 %, differences in lung function larger than 0.85 SD between both groups. SNP analyses did not reveal group differences or associations between SNP frequencies and pulmonary function among individuals with or without diabetes. This is most probably due to the modest effect sizes on lung function traits which were shown before in genome-wide association studies and the small sample size of the current study. Furthermore, impaired cardiovascular function could have contributed to the differences in lung function between both groups. In the absence of distinct measures for cardiovascular performance, such as echocardiographic parameters or biomarkers like N-terminal pro-brain natriuretic peptide, the calculated surrogate parameter for cardiovascular function, O 2 -pulse, revealed no differences between both groups.
In conclusion, these data indicate that patients with newly diagnosed and well-controlled type 2 diabetes mellitus exhibit features of obstructive ventilation pattern indicating reduced lung function, which may at least in part relate to glucotoxicity.
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